Study on the Diagnosis and Management of CLL in Italy by GIMEMA
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04867915|
Recruitment Status : Not yet recruiting
First Posted : April 30, 2021
Last Update Posted : April 30, 2021
retrospective and prospective multicenter observational clinical and biological data collection from all patients with newly diagnosed CLL, SLL or MBL.
retrospective cohort: all cases with a diagnosis between January 1st 2010 and August 31th 2021.
prospective cohort: all patients with a diagnosis between September 1st 2021 and September 1st 2025.
|Condition or disease|
|Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type|
|Study Type :||Observational|
|Estimated Enrollment :||12500 participants|
|Official Title:||Observational Study on the Diagnosis and Management of Chronic Lymphocytic Leukemia (CLL) in Italy by Gruppo Italiano Malattie EMatologiche Dell'Adulto (GIMEMA)|
|Estimated Study Start Date :||July 2021|
|Estimated Primary Completion Date :||July 2026|
|Estimated Study Completion Date :||July 2026|
- Describe the diagnosis and management of CLL patients [ Time Frame: at 1 year for the prospective cohort and at 4 years for the retrospective cohort ]evaluation of CLL management in terms of time to first treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04867915
|Contact: Paola Faziemail@example.com|
|Contact: Enrico Creafirstname.lastname@example.org|